RecruitingNot ApplicableNCT06772220
Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease
Sponsor
Oregon Health and Science University
Enrollment
150 participants
Start Date
Mar 5, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.
Eligibility
Min Age: 40 YearsMax Age: 90 Years
Inclusion Criteria8
- Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
- Currently treated with levodopa at a minimum dose of 300 mg/day
- Montreal Cognitive Assessment (MOCA) ≥15
- Demonstrated capacity to provide informed consent.
- years of age
- Estimated glomerular filtration rate ≥60
- Absence of uncontrolled hypertension in medical history
- Absence of insulin use
Exclusion Criteria1
- \-
Interventions
DIETARY_SUPPLEMENTFolic Acid 1 MG
Folic Acid 1mg per day
DIETARY_SUPPLEMENTVitamin B6 25 MG
Vitamin B6, 25mg per day
DIETARY_SUPPLEMENTVitamin B12
Vitamin B12, 1,000 ug per day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06772220